#ASC30

Thiard News@F4F

@newsen.bsky.social

5 days ago

Ascletis Unveils Promising Results for ASC30 in Obesity Treatment from Phase II Study Ascletis Pharma reveals significant findings from its Phase II study of ASC30, a novel treatment for obesity, showing substantial weight loss without weekly injections.

Ascletis Unveils Promising Results for ASC30 in Obesity Treatment from Phase II Study #USA #California #Ascletis #Obesity_Treatment #ASC30

Thiard News@F4F

@newsen.bsky.social

1 month ago

Ascletis Begins Phase II Study for ASC30, a New Diabetes Treatment Ascletis Pharma has initiated a Phase II study for ASC30, an oral GLP-1R agonist, targeting diabetes treatment. Topline results expected Q3 2026.

Ascletis Begins Phase II Study for ASC30, a New Diabetes Treatment #USA #Various_States #Ascletis #diabetes #ASC30

Thiard News@F4F

@newsen.bsky.social

2 months ago

Ascletis Gains FDA Clearance for Groundbreaking Diabetes Study of ASC30 Ascletis Pharma receives FDA IND approval for a Phase II trial of ASC30, a potential GLP-1 therapy for diabetes. Start of enrollment is anticipated in early 2026.

Ascletis Gains FDA Clearance for Groundbreaking Diabetes Study of ASC30 #USA #Ascletis #ASC30 #FDA_IND #Multiple_Sites

Thiard News@F4F

@newsen.bsky.social

3 months ago

Ascletis' ASC30 Shows Promising Weight Loss Results in Phase II Trial for Obesity Management Ascletis Pharma's ASC30, an oral GLP-1 receptor agonist, exhibited significant weight loss results and improved gastrointestinal tolerability in a Phase II trial.

Ascletis' ASC30 Shows Promising Weight Loss Results in Phase II Trial for Obesity Management #USA #None #GLP-1 #Ascletis #ASC30

Thiard News@F4F

@newsen.bsky.social

4 months ago

Ascletis Reveals Promising Results of Obesity Treatments at ObesityWeek® 2025 Ascletis Pharma showcases significant findings from studies on ASC30 and combinations of ASC31 and ASC47, heralding advancements in obesity treatment.

Ascletis Reveals Promising Results of Obesity Treatments at ObesityWeek® 2025 #USA #Atlanta #Ascletis #ASC30 #ObesityWeek

Thiard News@F4F

@newsen.bsky.social

4 months ago

Ascletis to Unveil New Obesity Treatments at ObesityWeek® 2025 Conference Ascletis to showcase results of ASC30 oral tablet and injection, along with ASC31 and ASC47 combination at ObesityWeek® 2025, Atlanta.

Ascletis to Unveil New Obesity Treatments at ObesityWeek® 2025 Conference #USA #Atlanta #ASC30 #Ascletis_Pharma #ObesityWeek

Thiard News@F4F

@newsen.bsky.social

4 months ago

Ascletis Advances Obesity Treatment with Phase IIa Clinical Study Enrollment Completion Ascletis has successfully enrolled participants for its Phase IIa clinical trial evaluating its once-monthly GLP-1R agonist ASC30 for obesity treatment.

Ascletis Advances Obesity Treatment with Phase IIa Clinical Study Enrollment Completion #USA #Hong_Kong #Ascletis #ASC30 #GLP-1R

Thiard News@F4F

@newsen.bsky.social

5 months ago

Ascletis Unveils Promising Results for ASC30 in Body Weight Management Study at EASD 2025 Ascletis Pharma presents positive findings from a recent clinical study of ASC30, showcasing its effectiveness and safety in weight management.

Ascletis Unveils Promising Results for ASC30 in Body Weight Management Study at EASD 2025 #Hong_Kong #Ascletis #ASC30 #EASD

Thiard News@F4F

@newsen.bsky.social

6 months ago

Ascletis Announces Promising ASC30 With a 75-Day Half-Life for Obesity Management Ascletis Pharma reveals that its ASC30 formulation has a 75-day half-life, paving the way for once-quarterly obesity treatment options.

Ascletis Announces Promising ASC30 With a 75-Day Half-Life for Obesity Management #China #Hong_Kong #Ascletis #ASC30 #GLP-1R

Thiard News@F4F

@newsen.bsky.social

6 months ago

Ascletis to Share Promising Data on ASC30 at EASD Annual Meeting Ascletis Pharma announces the presentation of ASC30 study results at the EASD Annual Meeting, showcasing potential in obesity treatment.

Ascletis to Share Promising Data on ASC30 at EASD Annual Meeting #Hong_Kong #Ascletis #ASC30 #EASD

Thiard News@F4F

@newsen.bsky.social

6 months ago

Ascletis Unveils Promising Results for ASC30 in Obesity Treatment Phase Ib Study Ascletis Pharma has announced compelling pharmacokinetic data for its ASC30 once-daily tablet in a recent Phase Ib trial, indicating improved weight loss potential compared to current treatments.

Ascletis Unveils Promising Results for ASC30 in Obesity Treatment Phase Ib Study #Hong_Kong #obesity #Ascletis #ASC30

@drtimos.bsky.social

6 months ago

Obesity Weekly News – August 12th 2025 Obesity Update: Ascletis’ ASC30, Hanmi’s CRF2 Breakthrough, Orforglipron’s 27-Pound Loss, Mounjaro’s Korea Launch & More In this week’s Obesity Updates, […] The post Obesity Weekly News – August 12th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Obesity Weekly News – August 12th 2025 #News #ASC30 #Orforglipron #CRF2 #clinicaltrials Comment below!

@drtimos.bsky.social

7 months ago

Obesity Weekly News – August 12th 2025 Obesity Update: Ascletis’ ASC30, Hanmi’s CRF2 Breakthrough, Orforglipron’s 27-Pound Loss, Mounjaro’s Korea Launch & More In this week’s Obesity Updates, […] The post Obesity Weekly News – August 12th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Obesity Weekly News – August 12th 2025 #News #ASC30 #Orforglipron #CRF2 #clinicaltrials Comment below!

@drtimos.bsky.social

7 months ago

Obesity Weekly News – August 12th 2025 Obesity Update: Ascletis’ ASC30, Hanmi’s CRF2 Breakthrough, Orforglipron’s 27-Pound Loss, Mounjaro’s Korea Launch & More In this week’s Obesity Updates, […] The post Obesity Weekly News – August 12th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Obesity Weekly News – August 12th 2025 #News #ASC30 #Orforglipron #CRF2 #clinicaltrials Comment below!

@drtimos.bsky.social

7 months ago

Obesity Weekly News – July 29th 2025 Obesity Update: Once-Monthly ASC30 Trial, Viking’s Phase III Launch, Generic Wegovy Win & More In this week’s Obesity Updates, we […] The post Obesity Weekly News – July 29th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Obesity Weekly News – July 29th 2025 #News #ASC30 #glp1 #ObesityResearch #RochePharma Comment below!

Thiard News@F4F

@newsen.bsky.social

7 months ago

Ascletis Pharma's Phase IIa Study Enrollment for ASC30 Oral Treatment in Obesity Completed Ascletis has completed the enrollment of 125 participants in a U.S. Phase IIa study of ASC30, exploring its effectiveness for obesity treatment. Topline data expected in late 2025.

Ascletis Pharma's Phase IIa Study Enrollment for ASC30 Oral Treatment in Obesity Completed #United_States #N/A #obesity #Ascletis #ASC30

@drtimos.bsky.social

7 months ago

Obesity Weekly News – July 29th 2025 Obesity Update: Once-Monthly ASC30 Trial, Viking’s Phase III Launch, Generic Wegovy Win & More In this week’s Obesity Updates, we […] The post Obesity Weekly News – July 29th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Obesity Weekly News – July 29th 2025 #News #ASC30 #glp1 #ObesityResearch #RochePharma Comment below!

@drtimos.bsky.social

7 months ago

Obesity Weekly News – July 29th 2025 Obesity Update: Once-Monthly ASC30 Trial, Viking’s Phase III Launch, Generic Wegovy Win & More In this week’s Obesity Updates, we […] The post Obesity Weekly News – July 29th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Obesity Weekly News – July 29th 2025 #News #ASC30 #glp1 #ObesityResearch #RochePharma Comment below!

Thiard News@F4F

@newsen.bsky.social

7 months ago

Ascletis Initiates Phase IIa Study of Innovative Obesity Drug ASC30 in the U.S. Ascletis Pharma has started its Phase IIa study for ASC30, a monthly obesity treatment. Initial dosing completed among participants with weight-related comorbidities.

Ascletis Initiates Phase IIa Study of Innovative Obesity Drug ASC30 in the U.S. #United_States #Hong_Kong #Ascletis #Obesity_Treatment #ASC30

Thiard News@F4F

@newsen.bsky.social

8 months ago

Ascletis Initiates Phase IIa Study on ASC30 for Weight Management in Overweight Patients Ascletis Pharma begins a 13-week study of ASC30, an oral GLP-1R agonist aimed at aiding weight loss in obese participants. Results are expected late 2025.

Ascletis Initiates Phase IIa Study on ASC30 for Weight Management in Overweight Patients #Hong_Kong #Ascletis #ASC30 #GLP-1R_Agonist

Thiard News@F4F

@newsen.bsky.social

9 months ago

Ascletis Showcases Breakthrough Research on Diabetes Treatment at 85th ADA Scientific Sessions Ascletis Pharma presents cutting-edge findings on its diabetes treatment candidates ASC30 and ASC47 at the upcoming ADA Scientific Sessions in Chicago.

Ascletis Showcases Breakthrough Research on Diabetes Treatment at 85th ADA Scientific Sessions #USA #Chicago #Ascletis #ASC47 #ASC30

Thiard News@F4F

@newsen.bsky.social

10 months ago

Ascletis Reveals Promising Results for ASC30 in Weight Management Trials Ascletis Pharma has reported encouraging outcomes from their Phase Ib trial of ASC30, a small molecule GLP-1R agonist for obesity treatment, paving the way for future studies.

Ascletis Reveals Promising Results for ASC30 in Weight Management Trials #Ascletis #ASC30 #GLP-1R

Thiard News@F4F

@newsen.bsky.social

11 months ago

Ascletis Pharma's ASC30 Shows Promising Results in U.S. Phase Ib Obesity Trial Ascletis Pharma has announced encouraging interim results from its Phase Ib study of ASC30, a GLP-1R agonist, showing a potential monthly injection for obesity.

Ascletis Pharma's ASC30 Shows Promising Results in U.S. Phase Ib Obesity Trial #United_States #Hong_Kong #ASC30 #Ascletis_Pharma #GLP-1R

Thiard News@F4F

@newsen.bsky.social

11 months ago

Ascletis Pharma Set to Host a Comprehensive Webinar on Obesity Treatments in 2025 Join Ascletis Pharma's informative webinar on April 2, 2025. The session covers their obesity portfolio, featuring the promising drug ASC30.

Ascletis Pharma Set to Host a Comprehensive Webinar on Obesity Treatments in 2025 #China #Hong_Kong #Ascletis #ASC30 #Obesity_Webinar

Thiard News@F4F

@newsen.bsky.social

1 year ago

Ascletis Reports Positive Interim Findings in Phase Ib Trial of ASC30 for Weight Loss Treatment Ascletis Pharma has highlighted encouraging interim results from the Phase Ib study of ASC30, an oral medication for obesity treatment, showing significant weight loss.

Ascletis Reports Positive Interim Findings in Phase Ib Trial of ASC30 for Weight Loss Treatment #USA #Hong_Kong #Obesity_Treatment #ASC30 #Ascletis_Pharma

Thiard News@F4F

@newsen.bsky.social

1 year ago

Ascletis Reports Encouraging Results from ASC30 Trials for Obesity Treatment Ascletis Pharma reveals promising findings from the ASC30 oral tablet trials for obesity, showcasing beneficial pharmacokinetic properties and safety profiles.

Ascletis Reports Encouraging Results from ASC30 Trials for Obesity Treatment #USA #Hong_Kong #obesity #Ascletis #ASC30